Screening for Hepatitis B: Serology Markers Interpretation

Cadet, Myriam Jean

doi:10.1177/2165079918794707

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV is an enveloped virus that has a partially double-stranded circular DNA genome ranging from 3.0 to 3.4 kilobases (kb) [ 30 , 31 , 32 ]. The structural size of the HBV virus was first demonstrated in the serum of patients with Australia-antigen-associated hepatitis by Dane et al when they published the electron microscope images of the particles in 1970 [ 33 ].…”

Section: Diagnosis Of Hbvmentioning

confidence: 99%

“…The presence of these serological biomarkers will not only determine the infection, but also the clinical phase, either acute or chronic infection, in patients [ 39 ]. The biomarkers of HBV consist of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HbsAb or Anti-HBs), hepatitis B envelop antigen (HbeAg), hepatitis B envelop antibody (HbeAb), hepatitis B core antigen (HbcAg) and hepatitis B core antibody (HbcAb or Anti-HBc) [ 30 , 40 ]. HBV DNA measurement is a direct indicator of the viral load.…”

Section: Diagnosis Of Hbvmentioning

confidence: 99%

See 1 more Smart Citation

Lateral Flow Assay for Hepatitis B Detection: A Review of Current and New Assays

2023

View full text Add to dashboard Cite

From acute to chronic hepatitis, cirrhosis, and hepatocellular cancer, hepatitis B infection causes a broad spectrum of liver diseases. Molecular and serological tests have been used to diagnose hepatitis B-related illnesses. Due to technology limitations, it is challenging to identify hepatitis B infection cases at an early stage, particularly in a low- and middle-income country with constrained resources. Generally, the gold-standard methods to detect hepatitis B virus (HBV) infection requires dedicated personnel, bulky, expensive equipment and reagents, and long processing times which delay the diagnosis of HBV. Thus, lateral flow assay (LFA), which is inexpensive, straightforward, portable, and operates reliably, has dominated point-of-care diagnostics. LFA consists of four parts: a sample pad where samples are dropped; a conjugate pad where labeled tags and biomarker components are combined; a nitrocellulose membrane with test and control lines for target DNA-probe DNA hybridization or antigen-antibody interaction; and a wicking pad where waste is stored. By modifying the pre-treatment during the sample preparation process or enhancing the signal of the biomarker probes on the membrane pad, the accuracy of the LFA for qualitative and quantitative analysis can be improved. In this review, we assembled the most recent developments in LFA technologies for the progress of hepatitis B infection detection. Prospects for ongoing development in this area are also covered.

show abstract